# AEGEAN (NCT03800134)

> A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03800134
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Non-Small Cell Lung Cancer
- Interventions: Durvalumab; Placebo; Carboplatin; Cisplatin; Pemetrexed; Paclitaxel; Gemcitabine; Surgery
- Enrollment: 825
- Primary outcome: Pathological Complete Response (pCR) in modified intent-to-treat (mITT) population
- Primary outcome: Event-Free Survival (EFS) in modified intent to treat (mITT) population

## Commentary we found

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=aegean-nct03800134